Author(s): Walker LM, Burton DR
Abstract Share this page
Abstract Many antiviral vaccines elicit neutralizing antibodies as a correlate of protection. For HIV, given the huge variability of the virus, it is widely believed that the induction of a broadly neutralizing antibody (bNAb) response will be crucial in a successful vaccine against the virus. Unfortunately, despite many efforts, the development of an immunogen that elicits bNAbs remains elusive. However, recent structural studies of HIV-1 Env proteins, generation of novel bNAbs, maturation of technologies for the isolation of further antibodies, insights into the requirements for antibody-mediated protection, and novel vaccination approaches are providing grounds for renewed optimism. Copyright 2010 Elsevier Ltd. All rights reserved.
This article was published in Curr Opin Immunol
and referenced in Journal of Proteomics & Bioinformatics